Filing Details

Accession Number:
0001127602-23-011265
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-24 08:53:46
Reporting Period:
2023-03-22
Accepted Time:
2023-03-24 08:53:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1878313 Maia Biotechnology Inc. MAIA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1913199 Stan Smith 444 West Lake Street, Suite 1700
Chicago IL 60606
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-22 1,458 $3.18 540,528 No 4 P Indirect See Footnote
Common Stock Acquisiton 2023-03-23 1,862 $3.43 542,390 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Footnotes
  1. The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
  2. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.07 to $3.39, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  3. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.11 to $3.51, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.